Mesoblast Still Hopes To Show Utility Of Allogeneic Stem Cell Therapy In COVID-19

Although its 300-patient, Phase III trial is not likely to reduce mortality, Australian firm says the full dataset may show potential for off-the-shelf cell therapy in acute respiratory distress syndrome.